News
-
-
-
-
PRESS RELEASE
Capital B confirms the acquisition of 37 BTC for EUR 2.3 million, the holding of a total of 2,925 BTC, and a BTC Yield of 1.25% YTD
Capital B announces completion of OCA B-01 conversion by Blockstream Capital Partners and UTXO Management. Subscription and exercise of shares, BTC acquisition, and BTC performance update -
PRESS RELEASE
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene completes patient randomization in Phase 2 of clinical trial for TG4050 in adjuvant treatment of head and neck cancer. Top-line results expected by Q1 2028 -
PRESS RELEASE
The Burkhalter Group exceeds expectations once again by posting excellent results for the 2025 financial year
Burkhalter Group exceeds expectations in 2025 with strong financial performance, proposing a dividend increase and targeting acquisitions. Focus on sustainability and positive outlook for 2026 -
-
-
PRESS RELEASE
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE)
BioVersys AG and partners publish pre-clinical development data of AlpE in Nature Communications, showcasing unique Mechanism of Action targeting drug-resistance in tuberculosis -
